<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04897386</url>
  </required_header>
  <id_info>
    <org_study_id>duvalizumab</org_study_id>
    <nct_id>NCT04897386</nct_id>
  </id_info>
  <brief_title>Monitoring the Efficacy of Duvalizumab Combined With Neoadjuvant Chemotherapy for Ib-IIIb NSCLC by Sequencing of Immune Receptor Repertoire: a Prospective, One Arm Clinical Study</brief_title>
  <official_title>Monitoring the Efficacy of Duvalizumab Combined With Neoadjuvant Chemotherapy for Ib-IIIb NSCLC by Sequencing of Immune Receptor Repertoire: a Prospective, One Arm Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan Union Hospital, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe and evaluate the efficacy and safety of Duvalizumab Combined With Neoadjuvant&#xD;
      Chemotherapy for Ib-IIIb NSCLC and the relevance with Immune Receptor Repertoire&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>at 64th week</time_frame>
    <description>Objective response rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DFS</measure>
    <time_frame>at 64th week</time_frame>
    <description>disease free survival</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ib-IIIb NSCLC</condition>
  <arm_group>
    <arm_group_label>Duvalizumab Combined With Neoadjuvant Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duvalizumab</intervention_name>
    <description>Pemetrexed 850 mg, IV, Day1; Platinum 50mg / m2, IV, day1, once every 3 weeks, duvalizumab treatment, 1500mg, day1, a total of 4 cycles, once every 3 weeks. 4 cycles in total</description>
    <arm_group_label>Duvalizumab Combined With Neoadjuvant Chemotherapy</arm_group_label>
    <other_name>Pemetrexed</other_name>
    <other_name>platinum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: ≥ 18 years old;&#xD;
&#xD;
          2. NSCLC confirmed by histopathology;&#xD;
&#xD;
          3. According to the doctor's advice, according to the routine diagnosis and treatment&#xD;
             process, lung cancer patients who need radical resection and neoadjuvant therapy&#xD;
             before operation;&#xD;
&#xD;
          4. No previous treatment for esophageal cancer, including surgery, chemotherapy,&#xD;
             radiotherapy, targeted therapy, hormone or immunotherapy;&#xD;
&#xD;
          5. ECoG score was 0 or 1;&#xD;
&#xD;
          6. There was no operative contraindication in preoperative organ function examination;&#xD;
&#xD;
          7. At least 6 months of expected survival&#xD;
&#xD;
          8. The laboratory examination met the following standards:&#xD;
&#xD;
               1. Bone marrow function: hemoglobin (HB) ≥ 90g / L; White blood cell count (WBC) ≥&#xD;
                  the lower limit of normal value; Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L；&#xD;
                  Platelet count ≥ 90 × 10^9/L；&#xD;
&#xD;
               2. Renal function: Cr ≤ unl (upper limit of normal value) × 5, CCR ≥ 55ml / min;&#xD;
&#xD;
               3. Liver function: total bilirubin ≤ ULN × 1.5； ALT and AST ≤ ULN × 2.5 (patients&#xD;
                  with liver metastasis can be relaxed to ≤ 5 * ULN);&#xD;
&#xD;
               4. Coagulation function: international normalized ratio of prothrombin time ≤ ULN ×&#xD;
                  5, and partial thromboplastin time was within the normal range;&#xD;
&#xD;
          9. The subjects agreed and voluntarily signed the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergic to the study drug;&#xD;
&#xD;
          2. History of hemorrhagic disease or with hemorrhagic disease&#xD;
&#xD;
          3. Liver and kidney dysfunction;&#xD;
&#xD;
          4. Patients with uncontrolled diseases (including but not limited to: active infection,&#xD;
             symptomatic congestive heart failure; Myocardial infarction occurred within 3 months;&#xD;
             Unstable angina, arrhythmia, etc.);&#xD;
&#xD;
          5. Women of childbearing age are unwilling to use contraception;&#xD;
&#xD;
          6. Lactating women;&#xD;
&#xD;
          7. For any other reason, the researchers consider it inappropriate to participate in the&#xD;
             trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaorong Dong, PhD</last_name>
    <phone>027-85872859</phone>
    <email>xiaorongdong@hust.edu.cn</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>May 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan Union Hospital, China</investigator_affiliation>
    <investigator_full_name>Xiaorong Dong</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

